Attendees will learn:

Molecular mechanisms of currently used immunosuppressive drugs used to inhibit T cell activation in transplant patients
Use of immune monitoring assays to either predict or detect the presence of acute and/or chronic graft injury in transplant patients
Newly developed immunosuppressive reagents that are being incorporated into treatment strategies in the clinic as well as reagents in the pipe line that will potentially be used in transplantation
What transplant tolerance is and what it is not
Cellular and molecular mechanisms underlying the establishment of transplant tolerance in preclinical models
How transplant patients may become tolerant and how the development and/or establishment of tolerance in clinical transplantation are assessed

Dr. Ronald Gill PhD

University of Colorado Denver